[Prevention of cervical cancer].
作者信息
Marzo-Castillejo M, Cierco Peguero P, del Cura González I
机构信息
Divisió de Atenció Primària, Institut Català de la Salut, Grupo de Cáncer PAPPS-semFYC, Barcelona, Spain.
出版信息
Aten Primaria. 2005 Oct 15;36(6):328-33. doi: 10.1157/13079868.
Abstract
摘要
相似文献
1
[Prevention of cervical cancer].
Aten Primaria. 2005 Oct 15;36(6):328-33. doi: 10.1157/13079868.
2
The renewal of the National Cervical Screening Program.
Med J Aust. 2016 Oct 17;205(8):357-358. doi: 10.5694/mja16.00820.
3
Cervical cancer can be controlled.
East Afr Med J. 2001 Feb;78(2):53-4. doi: 10.4314/eamj.v78i2.9087.
4
Are we ready for a paradigm change in cervical cancer screening?
Lancet. 2003 Dec 6;362(9399):1866-7. doi: 10.1016/S0140-6736(03)14996-3.
5
Cervical cancer screening in older women.
Clin J Oncol Nurs. 2006 Feb;10(1):31-3. doi: 10.1188/06.CJON.31-33.
6
Global challenges of cervical cancer prevention.
Eur J Gynaecol Oncol. 2000;21(6):533-9.
7
Pitfalls in the screening and early diagnosis of cervical cancer.
Curr Opin Obstet Gynecol. 1990 Feb;2(1):74-9.
8
Rightsizing cervical cancer screening: comment on "Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone".
Arch Intern Med. 2010 Jun 14;170(11):985-6. doi: 10.1001/archinternmed.2010.133.
9
[HPV test for quality control of gynecologic cytological tests].
Lakartidningen. 2008;105(48-49):3560, 3564.
10
Whatever happened to the annual pap smear?
R I Med J (2013). 2013 Jan 4;96(1):36-8.
引用本文的文献
1
[Cervical cancer screening: Is active recruitment worth the effort?].
Aten Primaria. 2015 Dec;47(10):653-8. doi: 10.1016/j.aprim.2014.12.006. Epub 2015 Mar 29.
本文引用的文献
1
Cervical cancer screening programmes and policies in 18 European countries.
Br J Cancer. 2004 Aug 31;91(5):935-41. doi: 10.1038/sj.bjc.6602069.
2
Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis.
Health Technol Assess. 2004 May;8(20):iii, 1-78. doi: 10.3310/hta8200.
3
[Use of pap smear for cervical cancer screening and factors related with its use in Spain].
Aten Primaria. 2004 Mar 31;33(5):229-34. doi: 10.1016/s0212-6567(04)79407-x.
4
Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening.
Obstet Gynecol. 2004 Feb;103(2):304-9. doi: 10.1097/01.AOG.0000109426.82624.f8.
5
Risk of cervical cancer associated with extending the interval between cervical-cancer screenings.
N Engl J Med. 2003 Oct 16;349(16):1501-9. doi: 10.1056/NEJMoa035419.
6
Human papillomavirus: epidemiology and public health.
Arch Pathol Lab Med. 2003 Aug;127(8):930-4. doi: 10.5858/2003-127-930-HPEAPH.
7
European Code Against Cancer and scientific justification: third version (2003).
Ann Oncol. 2003 Jul;14(7):973-1005. doi: 10.1093/annonc/mdg305.
8
Chapter 13: Primary screening of cervical cancer with human papillomavirus tests.
J Natl Cancer Inst Monogr. 2003(31):89-96. doi: 10.1093/oxfordjournals.jncimonographs.a003488.
9
Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality.
J Natl Cancer Inst Monogr. 2003(31):3-13. doi: 10.1093/oxfordjournals.jncimonographs.a003479.
10
A controlled trial of a human papillomavirus type 16 vaccine.
N Engl J Med. 2002 Nov 21;347(21):1645-51. doi: 10.1056/NEJMoa020586.
Zotero 插件